Hypoimmune FK binding protein 12-knockout CD19 CAR T cells achieve deep tissue B-cell depletion and control Nalm6 tumors in immunosuppressed humanized mice

Overview
This paper describes the engineering of allogeneic CD19 CAR T cells with FKBP12 knockout to resist mTOR inhibitors like tacrolimus and rapamycin. The study utilized 24-well G-Rex® plates for the recovery and expansion of nucleofected T cells. These cells demonstrated deep B-cell depletion in immunosuppressed mice.
What this paper found
Allogeneic CD19 CAR T cells that combine hypoimmune editing (HLA class I and II depletion with CD47 overexpression) with FKBP12 knockout stayed active in the presence of tacrolimus and rapamycin and controlled Nalm6 leukemia in immunosuppressed humanized mice. In vitro, FKBP12-knockout cells killed B cells and Nalm6 cells at high drug concentrations, while unedited CAR T cells failed. Hypoimmune cells also avoided allogeneic T-cell, NK-cell and macrophage responses. Mice received 350,000 CAR T cells three days after 50,000 Nalm6 cells. Over 25 days, only hypoimmune FKBP12-knockout cells prevented tumor expansion in all 5 mice, engrafted in spleen and bone marrow, and depleted bone marrow CD19+ cells.
Note: Preclinical study in humanized mice with small groups of 3 to 5 animals; the authors state that animals within the same group showed consistent outcomes and that clinical assessment should come next.
In stark contrast, HIP-FKBPKO CAR T cells reliably prevented Nalm6 expansion in all 5 mice of that group (Figure 5G). — Xiaomeng Hu, Andrew McAlister, Jeremy Kinder, Adam Johnson, Kathy White, Carolin B. Caruso, Chenyan Wang, Ron Basco, Corie Gattis, Annabelle Friera, Tobias Deuse, Sonja Schrepfer, Cytotherapy
Study details
- Authors
- Xiaomeng Hu, Andrew McAlister, Jeremy Kinder, Adam Johnson, Kathy White, Carolin B. Caruso, Chenyan Wang, Ron Basco, Corie Gattis, Annabelle Friera, Tobias Deuse, Sonja Schrepfer
- Institution
- Sana Biotechnology Inc., South San Francisco, CA, USA · Department of Surgery, Division of Cardiothoracic Surgery, Transplant and Stem Cell Immunobiology (TSI)-Lab, University of California San Francisco, San Francisco, California, USA
- Journal
- Cytotherapy
- Year
- 2025
- PMID / PMC
- PMID: 40650653
- G-Rex® model(s)
- G-Rex®24 Well Plate
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy
- Study phase
- Preclinical
How G-Rex® was used
After CRISPR/Cas9 nucleofection of lentivirally transduced CD4+ and CD8+ T cells, the edited cells were recovered and transferred to 24-well G-Rex® plates. Cells were split and IL-2 was replenished every 48 hours, with cryopreservation on day 8 post-activation.
Explore related
Full citation
Hu X, McAlister A, Kinder J, et al. Hypoimmune FK binding protein 12-knockout CD19 CAR T cells achieve deep tissue B-cell depletion and control Nalm6 tumors in immunosuppressed humanized mice. Cytotherapy. 2025;27(10):1190-1198.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.